Results 11 to 20 of about 477 (84)

4β-Hydroxycholesterol Signals From the Liver to Regulate Peripheral Cholesterol Transporters [PDF]

open access: yesFrontiers in Pharmacology, 2020
Activation of pregnane X receptor (PXR) elevates circulating 4β-hydroxycholesterol (4βHC), an agonist of liver X receptor (LXR). PXR may also regulate 25-hydroxycholesterol and 27-hydroxycholesterol.
Tuire Salonurmi   +21 more
doaj   +2 more sources

Liver X Receptor Agonist 4β‐Hydroxycholesterol as a Prognostic Factor in Coronary Artery Disease [PDF]

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Regardless of progress in treatment of coronary artery disease (CAD), there is still a significant residual risk of death in patients with CAD, highlighting the need for additional risk stratification markers.
Roosa Rahunen   +8 more
doaj   +2 more sources

Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation [PDF]

open access: yesJournal of Lipid Research, 2013
Several previous studies have shown that renal failure decreases not only renal elimination but also metabolic clearance of drugs, particularly those metabolized by CYP3A.
Yosuke Suzuki   +9 more
doaj   +2 more sources

Role of oxysterol 4β-hydroxycholesterol and liver X receptor alleles in pre-eclampsia [PDF]

open access: yesAnnals of Medicine
Background Liver X receptors (LXRs) are expressed in placenta and may be associated with pre-eclampsia (PE). Oxysterols act as agonists for LXRs. We recently proposed a new blood pressure-regulating circuit with oxysterol 4β-hydroxycholesterol (4βHC ...
Lassi Kaartinen   +13 more
doaj   +2 more sources

No impact of vitamin D on the CYP3A biomarker 4β-hydroxycholesterol in patients with abnormal glucose regulation. [PDF]

open access: yesPLoS ONE, 2015
PURPOSE:To investigate the effect of vitamin D3 on hepatic Cytochrome P450 enzyme (CYP) 3A4 in patients with abnormal glucose regulation using the endogenous marker 4β-hydroxycholesterol (4β-OHC):cholesterol ratio.
Buster Mannheimer   +3 more
doaj   +2 more sources

Estrogen associations with human pregnancy related increases in cytochrome P450 3A activity [PDF]

open access: yesFrontiers in Pharmacology
IntroductionIncreased CYP3A-mediated drug clearance during pregnancy can lead to subtherapeutic dosing of CYP3A substrates. Pregnancy-related hormones (PRHs) increase CYP3A4 expression and activity in cultured human hepatocytes.
Muluneh M. Fashe   +8 more
doaj   +2 more sources

PHENOTYPING CYP3A4/5 USING AN ENDOGENOUS BIOMARKER IN CHILDREN WITH DOWN SYNDROME [PDF]

open access: yesBulletin of Pharmaceutical Sciences. Assiut University, 2020
Background: Down syndrome (DS); a common chromosomal abnormality in humans can affect multiple organ systems. DS individuals usually use a wide range of medications.
Lateef Khan   +5 more
doaj   +1 more source

Sensitive UHPLC-MS/MS quantification method for 4β- and 4α-hydroxycholesterol in plasma for accurate CYP3A phenotyping

open access: yesJournal of Lipid Research, 2022
4β-Hydroxycholesterol (4β-OHC) is formed by Cytochrome P450 (CYP)3A and has drawn attention as an endogenous phenotyping probe for CYP3A activity. However, 4β-OHC is also increased by cholesterol autooxidation occurring in vitro due to dysregulated ...
Yosuke Suzuki   +10 more
doaj   +1 more source

On the rate of translocation in vitro and kinetics in vivo of the major oxysterols in human circulation

open access: yesJournal of Lipid Research, 2002
Oxysterols possess powerful biological activities. Some of their effects on the regulation of key enzymes are similar to those of cholesterol, but are much more potent.
Steve Meaney   +3 more
doaj   +1 more source

Risk assessment of drug–drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach

open access: yesClinical and Translational Science, 2022
Bintrafusp alfa, a first‐in‐class bifunctional fusion protein composed of the extracellular domain of TGF‐βRII (a TGF‐β “trap”) fused to a human IgG1 mAb blocking PD‐L1, is being evaluated for efficacy and safety in solid tumor indications as monotherapy
Yulia Vugmeyster   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy